EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis

Zhaoyan Chen, Fangyuan Tian

Frontiers in Public Health · 2024

DOI: 10.3389/fpubh.2024.1432947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2024. Verfasst von Zhaoyan Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Deoxycytidine, Cost-Benefit Analysis, Gemcitabine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin.

Methods

Data from a randomized controlled study in which individuals with metastatic GBC were treated with oxaliplatin and gemcitabine demonstrated improved survival. A Markov model is built to calculate the incremental cost–benefit ratio (ICER) from the viewpoint of Chinese society on the basis of clinical symptoms and disease development. One-way certainty and probability sensitivity analyses are used to describe the uncertainty in the model.

Results

Compared with those of fluorouracil (FU) and folinic acid, the utility value of modified oxaliplatin combined with gemcitabine increased by 0.22QALY throughout the course of the 10-year simulation (FA). In a Chinese healthcare setting, the cost-effectiveness ratio (ICER) is $52765.59/QALY, with a 0% chance of cost–benefit at the WTP (willing-to-pay) level of $37697.00/QALY. The ICERs predicted by sensitivity analysis were not significantly affected by cost variations related to the management of Grade 3–4 AEs, the diagnostics used, or hospitalization expenditures.

Conclusion

In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallbladder NeoplasmsDeoxycytidineCost-Benefit AnalysisGemcitabineOxaliplatinAntineoplastic Combined Chemotherapy ProtocolsMarkov ChainsHumansChinaQuality-Adjusted Life YearsFemaleMaleMiddle AgedCost-Effectiveness Analysis

Stichwörter der Autor:innen

cost effectivenessfluorouracilgallbladder cancer (GBC)gemcitabineoxaliplatin

Substanzen

DeoxycytidineGemcitabineOxaliplatin

Autor:innen und Institutionen

  • Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zitieren

APA

Chen, Z., & Tian, F. (2024). Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1432947

Vancouver

Chen Z, Tian F. Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1432947

BibTeX
@article{Chen2024,
  author = {Chen, Zhaoyan and Tian, Fangyuan},
  title = {Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis},
  journal = {Frontiers in Public Health},
  year = {2024},
  doi = {10.3389/fpubh.2024.1432947}
}
Kostenlos starten →